Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13720451 | 0.88 | KDM4E (0.45) | MAPTAKR1B1 | |
| SCHEMBL30795437 | 0.88 | ADRA1A (0.45) | MAPTSMN1; SMN2USP2LMNATSHR | |
| SCHEMBL1789505 | 0.88 | ADRA1A (0.45) | MAPTSMN1; SMN2USP2LMNATSHR | |
| SCHEMBL30796305 | 0.86 | TSHR (0.50) | MAPTSMN1; SMN2USP2LMNAPOLB | |
| SCHEMBL1791416 | 0.86 | TSHR (0.50) | MAPTSMN1; SMN2USP2LMNAPOLB | |
| SCHEMBL30796852 | 0.81 | TRPV1 (0.41) | MAPTSMN1; SMN2USP2LMNAPOLB | |
| SCHEMBL1789011 | 0.81 | TRPV1 (0.41) | MAPTSMN1; SMN2USP2LMNAPOLB | |
| SCHEMBL1790428 | 0.78 | ADRA1A (0.51) | AKR1B1CHRM1TSHR | |
| SCHEMBL30795062 | 0.78 | ADRA1A (0.51) | AKR1B1CHRM1TSHR | |
| SCHEMBL1788819 | 0.77 | TSHR (0.51) | AKR1B1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859549-B2 | Potassium channel modulators | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | claimed |
| WO-2012158399-A1 | CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-22 | — | — | WO | claimed |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | claimed |
| US-8859549-B2 | Potassium channel modulators | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2012158399-A1 | CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | MAPT 3246/4885SMN1; SMN2 1602/4885USP2 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.